# Dual Thrombolytic Therapy With Mutant Pro-urokinase and Low Dose Alteplase for Ischemic Stroke

> **NCT04256473** · PHASE2 · COMPLETED · sponsor: **Erasmus Medical Center** · enrollment: 200 (actual)

## Conditions studied

- Ischemic Stroke

## Interventions

- **DRUG:** mutant pro-urokinase
- **DRUG:** Alteplase

## Key facts

- **NCT ID:** NCT04256473
- **Lead sponsor:** Erasmus Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-10
- **Primary completion:** 2022-03-26
- **Final completion:** 2022-05-26
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2023-09-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04256473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04256473, "Dual Thrombolytic Therapy With Mutant Pro-urokinase and Low Dose Alteplase for Ischemic Stroke". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT04256473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*